Status:
TERMINATED
Senseye's OBCI Diagnostic Tool for PTSD
Lead Sponsor:
Senseye, Inc.
Conditions:
PTSD
Eligibility:
All Genders
18-65 years
Brief Summary
This pilot study will investigate the feasibility, acceptability, repeatability, accuracy and efficacy of the Senseye OBCI diagnostic tool to assess the presence and severity of PTSD symptoms and moni...
Detailed Description
This pilot study will investigate the feasibility, acceptability, repeatability, accuracy, and efficacy of operator-independent Senseye Ocular Brain-Computer Interface (OBCI) diagnostic tool to assess...
Eligibility Criteria
Inclusion
- Male/Female diagnosed with PTSD (only for PTSD group)
- aged 18- 65 years old
- able to read/write in English
Exclusion
- presence of intellectual disabilities
- psychotic or self-injurious behavior
- seizure disorder
- major depression
- traumatic brain injury (TBI)
- language disorder
- eye disorders
- other neurodevelopmental disorders
- history of lifetime psychosis
- mania
- current suicidality
- diagnosis of a substance use disorder
- impaired functioning to the degree that requires immediate initiation of psychotropic medication.
Key Trial Info
Start Date :
April 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 11 2023
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT05372523
Start Date
April 25 2022
End Date
January 11 2023
Last Update
April 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Olive View - UCLA Medical Center
Sylmar, California, United States, 91342